Dyadic's c1 production platform utilized in zapi study published in “vaccines” a leading peer-reviewed scientific journal

Jupiter, fla., june 28, 2021 (globe newswire) -- dyadic international, inc. (“dyadic”, “we”, “us”, “our”, or the “company”) (nasdaq: dyai), a global biotechnology company focused on deploying its proprietary c1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs, announced today findings from the zoonotic anticipation and preparedness initiative (zapi) project which has been published in vaccines, a leading peer-reviewed scientific journal.
DYAI Ratings Summary
DYAI Quant Ranking